{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:03:04Z","timestamp":1784750584089,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00280-016-3122-7","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T16:18:15Z","timestamp":1475079495000},"page":"921-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors"],"prefix":"10.1007","volume":"78","author":[{"given":"John","family":"Sarantopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fairooz","family":"Kabbinavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"3122_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","volume":"103","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211\u2013225","journal-title":"Cell"},{"key":"3122_CR2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1634\/theoncologist.8-6-531","volume":"8","author":"G Vlahovic","year":"2003","unstructured":"Vlahovic G, Crawford J (2003) Activation of tyrosine kinases in cancer. Oncologist 8:531\u2013538","journal-title":"Oncologist"},{"key":"3122_CR3","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0002-9440(10)64309-X","volume":"162","author":"HF Dvorak","year":"2003","unstructured":"Dvorak HF (2003) Rous-whipple award lecture. how tumors make bad blood vessels and stroma. Am J Pathol 162:1747\u20131757","journal-title":"Am J Pathol"},{"key":"3122_CR4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jcmm.12176","volume":"18","author":"WY Man","year":"2014","unstructured":"Man WY, Mak JP, Poon RY (2014) Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint. J Cell Mol Med 18:143\u2013155","journal-title":"J Cell Mol Med"},{"key":"3122_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2011.09.017","volume":"56","author":"H Huynh","year":"2012","unstructured":"Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM (2012) Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol 56:595\u2013601","journal-title":"J Hepatol"},{"key":"3122_CR6","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","volume":"11","author":"SH Lee","year":"2005","unstructured":"Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11:3633\u20133641","journal-title":"Clin Cancer Res"},{"key":"3122_CR7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","volume":"104","author":"FR Lamont","year":"2011","unstructured":"Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA (2011) Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 104:75\u201382","journal-title":"Br J Cancer"},{"key":"3122_CR8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-12-2885","volume":"19","author":"E Angevin","year":"2013","unstructured":"Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:1257\u20131268","journal-title":"Clin Cancer Res"},{"key":"3122_CR9","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-13-3006","volume":"20","author":"B Escudier","year":"2014","unstructured":"Escudier B, Grunwald V, Ravaud A, Ou YC, Castellano D, Lin CC, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E (2014) Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res 20:3012\u20133022","journal-title":"Clin Cancer Res"},{"key":"3122_CR10","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","volume":"17","author":"KB Kim","year":"2011","unstructured":"Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451\u20137461","journal-title":"Clin Cancer Res"},{"key":"3122_CR11","doi-asserted-by":"crossref","unstructured":"Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK (2012) A phase 2, multicenter, nonrandomized, open-label study of dovitinib (TKI258) in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. ASH Annual Meeting Abstracts: Abstract 4055","DOI":"10.1182\/blood.V120.21.4055.4055"},{"key":"3122_CR12","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","volume":"19","author":"F Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J (2013) Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 19:3693\u20133702","journal-title":"Clin Cancer Res"},{"key":"3122_CR13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-12-0999","volume":"12","author":"GE Konecny","year":"2013","unstructured":"Konecny GE, Kolarova T, O\u2019Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ (2013) Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 12:632\u2013642","journal-title":"Mol Cancer Ther"},{"key":"3122_CR14","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 F, Neven P, Musolino A, Latini L, Campone M, Cortes J, Barrios C, Squires M, Zhang Y, Deudon S, Gogov S, Blackwell K (2013) Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-)\/hormone receptor-positive (HR\u00a0+) breast cancer: a phase II, randomized, double blind, placebo-controlled study. San Antonio Breast Cancer Symposium Abstracts: Abstract OT2-6-04","DOI":"10.1158\/0008-5472.SABCS13-OT2-6-04"},{"key":"3122_CR15","unstructured":"Sharma S, Britten CD, Mortimer J, Kulkarni S, Quinlan M, Liu A, Scott JW, George D (in press) The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol"},{"key":"3122_CR16","doi-asserted-by":"crossref","unstructured":"Sharma S, Ramanathan RK, George DJ, Quinlan M, Kulkarni S, Homsi A, Scott JW, Infante JR (2013) A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258). J Clin Oncol 31:suppl; abstr 2593","DOI":"10.1200\/jco.2013.31.15_suppl.2593"},{"key":"3122_CR17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","volume":"15","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grunwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15:286\u2013296","journal-title":"Lancet Oncol"},{"key":"3122_CR18","unstructured":"National Institutes of Health and National Cancer Institute (2009) National cancer institute common terminology criteria for adverse events version 4.0"},{"key":"3122_CR19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3122-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3122-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3122-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:57:10Z","timestamp":1601110630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3122-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3122"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3122-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}